Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab
Conditions: Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma Interventions: Drug: ABBV-514; Drug: Pembrolizumab; Drug: Budigalimab Sponsor: AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Lung Cancer | Non-Small Cell Lung Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study